Newsfeeds - Spark Newswire

2 minute read

Oncolytics Biotech Partner Adlai Nortye Advances To The Second Dose Escalation Cohort Of The Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment In Breast Cancer

Today, 12:35 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety,

ONCY

2 minute read

Oncolytics Biotech Provides Enrollment Update On Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial At The 2022 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

By Benzinga Newsdesk

Today, 12:35 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers

ONCY

8 minute read

News

Oncolytics Biotech Releases A Letter To Shareholders

By Benzinga Newsdesk

Today, 12:35 PM

To the Shareholders of Oncolytics Biotech, 2021 generated ground-breaking data that creates the foundation for continued success in 2022 as we build our clinical opportunities and the data required to embark on our

ONCY

4 minute read

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO

By Shanthi Rexaline

Today, 12:35 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AMAM

4 minute read

The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill

By Shanthi Rexaline

Today, 12:35 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACXP

1 minute read

Oncolytics Biotech Q3 EPS $(0.09) Beats $(0.12) Estimate

By Benzinga Newsdesk

Today, 12:35 PM

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 25 percent increase over losses of $(0.12) per share from the

ONCY

6 minute read

Earnings Scheduled For November 5, 2021

By Benzinga Insights

Today, 12:35 PM

Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter.

AMCX

2 minute read

News

Oncolytics Biotech Announces Preclinical Data Demonstrating The Synergistic Immunotherapeutic Effects Of Pelareorep Combined With Radiotherapy

By Benzinga Newsdesk

Today, 12:35 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data

ONCY

6 minute read

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO

By Shanthi Rexaline

Today, 12:35 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)

ACAD

1 minute read

Oncolytics Biotech Q2 EPS $(0.13) Up From $(0.17) YoY

By Benzinga Newsdesk

Today, 12:35 PM

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.

ONCY